News | January 24, 2025
Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
PAT after MI is Rs. 41 crore which is 162% increase
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
This certification will open new markets for the Kwality Pharma
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
Subscribe To Our Newsletter & Stay Updated
